Solid Biosciences SLDB
NASDAQ SLDB
$6.47 +0.07 (+1.17%)
As of: Oct 21, 2026 · 11:41 AM EDT

Solid Biosciences (SLDB) Revenue (2021 - 2022)

Updated

Solid Biosciences' Revenue was $8.09 million in FY2022, down 40.6% from $13.62 million in FY2021.

Analysis

Solid Biosciences (SLDB) Revenue (2021 - 2022) Analysis & Trends

  • Per Business Quant data, Revenue in earlier years was $13.62 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 25.31 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 16.99 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 15.38 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn 7.80 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 15.03 Bn
10 Solid Biosciences 931.82 Mn -250.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 6.17 Mn
Jun 30, 2021 -13,000.00
Mar 31, 2021 -14,000.00
API Access

Solid Biosciences Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=SLDB&period=max&api_key=YOUR_API_KEY